Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus

Sasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, Murray B. Urowitz, Dafna D. Gladman, Paul R. Fortin, Edward H. Yelin, Ellen Ginzler, John G. Hanly, Christine Peschken, Caroline Gordon, Ola Nived, Cynthia Aranow, Sang Cheol Bae, David Isenberg, Anisur Rahman, James E. Hansen, Yvan St Pierre, Ann E. Clarke

Research output: Contribution to journalArticle

Abstract

Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.

Original languageEnglish (US)
Pages (from-to)393-396
Number of pages4
JournalJournal of Rheumatology
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Systemic Lupus Erythematosus
Lung Neoplasms
Smoking
Pharmaceutical Preparations
Ethics
Demography
Research Ethics Committees
Health

Keywords

  • Lung cancer
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Bernatsky, S., Ramsey-Goldman, R., Petri, M., Urowitz, M. B., Gladman, D. D., Fortin, P. R., ... Clarke, A. E. (2018). Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus. Journal of Rheumatology, 45(3), 393-396. https://doi.org/10.3899/jrheum.170652

Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus. / Bernatsky, Sasha; Ramsey-Goldman, Rosalind; Petri, Michelle; Urowitz, Murray B.; Gladman, Dafna D.; Fortin, Paul R.; Yelin, Edward H.; Ginzler, Ellen; Hanly, John G.; Peschken, Christine; Gordon, Caroline; Nived, Ola; Aranow, Cynthia; Bae, Sang Cheol; Isenberg, David; Rahman, Anisur; Hansen, James E.; Pierre, Yvan St; Clarke, Ann E.

In: Journal of Rheumatology, Vol. 45, No. 3, 01.03.2018, p. 393-396.

Research output: Contribution to journalArticle

Bernatsky, S, Ramsey-Goldman, R, Petri, M, Urowitz, MB, Gladman, DD, Fortin, PR, Yelin, EH, Ginzler, E, Hanly, JG, Peschken, C, Gordon, C, Nived, O, Aranow, C, Bae, SC, Isenberg, D, Rahman, A, Hansen, JE, Pierre, YS & Clarke, AE 2018, 'Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus', Journal of Rheumatology, vol. 45, no. 3, pp. 393-396. https://doi.org/10.3899/jrheum.170652
Bernatsky, Sasha ; Ramsey-Goldman, Rosalind ; Petri, Michelle ; Urowitz, Murray B. ; Gladman, Dafna D. ; Fortin, Paul R. ; Yelin, Edward H. ; Ginzler, Ellen ; Hanly, John G. ; Peschken, Christine ; Gordon, Caroline ; Nived, Ola ; Aranow, Cynthia ; Bae, Sang Cheol ; Isenberg, David ; Rahman, Anisur ; Hansen, James E. ; Pierre, Yvan St ; Clarke, Ann E. / Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus. In: Journal of Rheumatology. 2018 ; Vol. 45, No. 3. pp. 393-396.
@article{7c9cd9a9736147bf99dd6acf574cba29,
title = "Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus",
abstract = "Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0{\%} were in the highest SLEDAI quartile at baseline versus 40.8{\%} of lung cancer-free SLE controls. The vast majority (84.2{\%}) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1{\%} of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.",
keywords = "Lung cancer, Systemic lupus erythematosus",
author = "Sasha Bernatsky and Rosalind Ramsey-Goldman and Michelle Petri and Urowitz, {Murray B.} and Gladman, {Dafna D.} and Fortin, {Paul R.} and Yelin, {Edward H.} and Ellen Ginzler and Hanly, {John G.} and Christine Peschken and Caroline Gordon and Ola Nived and Cynthia Aranow and Bae, {Sang Cheol} and David Isenberg and Anisur Rahman and Hansen, {James E.} and Pierre, {Yvan St} and Clarke, {Ann E.}",
year = "2018",
month = "3",
day = "1",
doi = "10.3899/jrheum.170652",
language = "English (US)",
volume = "45",
pages = "393--396",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "3",

}

TY - JOUR

T1 - Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus

AU - Bernatsky, Sasha

AU - Ramsey-Goldman, Rosalind

AU - Petri, Michelle

AU - Urowitz, Murray B.

AU - Gladman, Dafna D.

AU - Fortin, Paul R.

AU - Yelin, Edward H.

AU - Ginzler, Ellen

AU - Hanly, John G.

AU - Peschken, Christine

AU - Gordon, Caroline

AU - Nived, Ola

AU - Aranow, Cynthia

AU - Bae, Sang Cheol

AU - Isenberg, David

AU - Rahman, Anisur

AU - Hansen, James E.

AU - Pierre, Yvan St

AU - Clarke, Ann E.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.

AB - Objective. To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. Methods.We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre. The ethics approval number for the Cancer Risk study is GEN-06-031. Results. Within these 14 SLE cohorts, 49 incident lung cancers occurred. Among lung cancer cases, 59.0% were in the highest SLEDAI quartile at baseline versus 40.8% of lung cancer-free SLE controls. The vast majority (84.2%) of SLE lung cancer cases were ever-smokers at baseline, versus 40.1% of those without lung cancer. In adjusted models, the principal factors associated with lung cancer were ever smoking (at cohort entry) and current age. Estimated adjusted effects of all drugs were relatively imprecise, but did not point toward any drug exposures as strong lung cancer risk factors. Conclusion. We saw no clear evidence for drugs as a trigger for lung cancer risk in SLE, although drug risk estimates were relatively imprecise. Smoking may be the most significant modifiable lung cancer risk factor in SLE.

KW - Lung cancer

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85042724497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042724497&partnerID=8YFLogxK

U2 - 10.3899/jrheum.170652

DO - 10.3899/jrheum.170652

M3 - Article

VL - 45

SP - 393

EP - 396

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 3

ER -